CD4 T cell antigens from Staphylococcus aureus newman strain identified following immunization with heat-killed bacteria

Clinical and Vaccine Immunology

Volumn 19, Issue 4, 2012, Pages 477-489

  Lawrence, Paulraj K ^a,c   Rokbi, Bachra ^b   Arnaud Barbe, Nadège ^b   Sutten, Eric L ^a   Norimine, Junzo ^a   Lahmers, Kevin K ^a   Brown, Wendy C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b SANOFI PASTEUR   (France)

^c Newport Laboratories R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT PROTEIN; STAPHYLOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; GENE REARRANGEMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE GENETICS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNIZATION; REVERSE GENETICS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 84859297309     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05642-11     Document Type: Article

References (98)

1. Abbott JR, Palmer GH, Howard CJ, Hope JC, Brown WC. 2004. Anaplasma marginale major surface protein 2 CD4 T cell epitopes are evenly distributed in conserved and hypervariable regions (HVR), whereas linear B-cell epitopes are predominantly located in the HVR. Infect. Immun. 72:7360-7366. (Pubitemid 39552415)
2. Almeida RA, Matthews KR, Cifrian E, Guidry AJ, Oliver SP. 1996. Staphylococcus aureus invasion of bovine mammary epithelial cells. J. Dairy Sci. 79:1021-1026. (Pubitemid 126429138)
3. Arrecubieta C, et al. 2008. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J. Infect. Dis. 198:571-575.
4. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2008. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. J. Bacteriol. 190:300-310.
5. Belardelli F. 1995. Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161-179.
6. Bergius RG, et al. 1993. Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. J. Immunol. 151:1463-1472.
7. Bradley LM, Dalton DK, Croft M. 1996. A direct role for IFN-γ in regulation of Th1 cell development. J. Immunol. 157:1350-1358. (Pubitemid 126449071)
8. Brown WC, et al. 2001. Highly conserved regions of the immunodominant major surface protein 2 of the genogroup II ehrlichial pathogen Anaplasma marginale are rich in naturally derived CD4 T lymphocyte epitopes that elicit strong recall responses. J. Immunol. 166:1114-1124. (Pubitemid 32060270)
9. + T lymphocyte and IgG2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge. Infect. Immun. 66:5406-5413.
10. Bubeck Wardenburg J, Williams WA, Missiakas D. 2006. Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 103:13831-13836. (Pubitemid 44413993)
11. Clarke SRK, et al. 2006. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 193:1098-1108.
12. Collen D, Stockx L, Lacroix H, Suy R, Vanderschueren S. 1997. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency. Circulation 95:463-472.
13. Croze M, et al. 2009. Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clin. Microbiol. Infect. 15:144-148.
14. Daum RS, Spellberg B. 2012. Progress toward a Staphylococcal aureus vaccine. Clin. Infect. Dis. 54:560-567.
15. de Neeling AJ, et al. 2007. High prevalence of methicillin resistant Staphylococcus aureus in pigs. Vet. Microbiol. 122:366-372. (Pubitemid 46756022)
16. Deresinski S, Herrera V. 2010. Immunotherapies for Staphylococcus aureus: current challenges and future prospects. Infect. Control Hosp. Epidemiol. 31(Suppl 1):S45-S47.
17. Dreisbach A, et al. 2010. Profiling the surfacome of Staphylococcus aureus. Proteomics 10:3082-3096.
18. Esen N, Wagoner G, Philips N. 2010. Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model. J. Neuroimmunol. 218:83-93.
19. Etz H, et al. 2002. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 99: 6573-6578. (Pubitemid 34526174)
20. Fattom A, et al. 1990. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect. Immun. 58:2367-2374. (Pubitemid 20212320)
21. Fattom A, et al. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023-1032. (Pubitemid 23059663)
22. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. 2004. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 22:880-887.
23. Flock JI. 1999. Extracellular-matrix-binding proteins as targets for the prevention of Staphylococcus aureus infections. Mol. Med. Today 5:532-537.
24. Flynn N, Cohen SH. 2008. The continuing saga of MRSA. J. Infect. Dis. 197:1217-1219. (Pubitemid 351632750)
25. Fournier B, Philpott DJ. 2005. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18:521-540. (Pubitemid 40995114)
26. Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. 1999. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin. Infect. Dis. 29:935-936. (Pubitemid 30256394)
27. Glass EJ, Oliver RA, Russell GC. 2000. Duplicated DQ haplotypes increase the complexity of restriction element usage in cattle. J. Immunol. 165:134-138. (Pubitemid 30429500)
28. Glowalla E, Tosetti B, Krönke M, Krut O. 2009. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect. Immun. 77:2719-2729.
29. Gómez MI, García VE, Gherardi MM, Cerquetti MC, Sordelli DO. 1998. Intramammary immunization with live-attenuated Staphylococcus aureus protects mice from experimental mastitis. FEMS Immunol. Med. Microbiol. 20:21-27. (Pubitemid 28075416)
30. Gómez MI, Sordelli DO, Buzzola FR, García VE. 2002. Induction of cell-mediated immunity to Staphylococcus aureus in the mouse mammary gland by local immunization with a live attenuated mutant. Infect. Immun. 70:4254-4260. (Pubitemid 34790934)
31. Gorak EJ, Yamada SM, Brown JD. 1999. Community-acquired methicillin- resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin. Infect. Dis. 29:797-800. (Pubitemid 30256370)
32. Gorwitz RJ. 2008. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update. Pediatr. Infect. Dis. J. 27:925-926.
33. Gorwitz RJ, et al. 2008. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 197:1226-1234. (Pubitemid 351632753)
34. Han S, et al. 2010. Anaplasma marginale infection with persistent highload bacteremia induces a dysfunctional memory CD4 T lymphocyte response but sustained high IgG titers. Clin. Vaccine Immunol. 17:1881-1890.
35. Harro C, et al. 2010. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from a first-in-human dose-ranging study. Clin. Vaccine Immunol. 17:1868-1874.
36. Harro JM, et al. 2010. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol. Med. Microbiol. 59:306-323.
37. Hensinger RN. 2006. Impending danger: community-acquired methicillin- resistant Staphylococcus aureus. J. Pediatr. Orthop. 26:701-702. (Pubitemid 44655533)
38. Hsieh CS, et al. 1993. Development of TH1 CD4 T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549.
39. Hume EBH, Dajcs JJ, Moreau JM, O'Callaghan RJ. 2000. Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect. Immun. 68:6052-6055.
40. Hutchings MI, Palmer T, Harrington DJ, Sutcliffe IC. 2009. Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em. Trends Microbiol. 17:13-21.
41. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184:1572-1580. (Pubitemid 33139743)
42. Khanna T, Friendship R, Dewey C, Weese JS. 2008. Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet. Microbiol. 128:298-303. (Pubitemid 351305091)
43. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. 2010. Nontoxic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J. Exp. Med. 207:1863-1870.
44. Kuklin N, et al. 2006. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74:2215-2223.
45. Kumanovics A, Tada T, Lindahl KF. 2003. Genomic organization of the mammalian MHC. Annu. Rev. Immunol. 21:629-657. (Pubitemid 37174543)
46. Kumarasamy KK, et al. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 9:597-602.
47. Kuroda M, Ohta T, Hayashi H. 1995. Isolation and the gene cloning of an alkaline shock protein in methicillin resistant Staphylococcus aureus. Biochem. Biophys. Res. Commun. 207:978-984.
48. Kusch K, et al. 2011. The influence of SaeRE and σ(B) on the expression of superantigens in different Staphylcoccus aureus isolates. Int. J. Med. Microbiol. 301:488-499.
49. Lahmers KK, Norimine J, Abrahamsen MS, Palmer GH, Brown WC. 2005. The CD4 T cell immunodominant Anaplasma marginale major surface protein 2 stimulates γδ T cell clones that express unique T cell receptors. J. Leukoc. Biol. 77:199-208. (Pubitemid 40315054)
50. Lewin HA, Russell GC, Glass EJ. 1999. Comparative organization and function of the major histocompatibility complex of domesticated cattle. Immunol. Rev. 167:145-158. (Pubitemid 29178977)
51. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
52. Liu, G. Y. 2009 Molecular pathogenesis of Staphylococcus aureus infection. Pediatr. Res. 65:71R-77R.
53. Lopez JE, et al. 2008. High-throughput identification of T-lymphocyte antigens from Anaplasma marginale expressed using in vitro transcription and translation. J. Immunol. Methods 332:129-141.
54. Lopez JE, et al. 2007. Immunogenicity of Anaplasma marginale type IV secretion system proteins. Infect. Immun. 75:2333-2342.
55. Lopez JE, et al. 2005. Identification of novel antigenic proteins in a complex Anaplasma marginale outer membrane immunogen by mass spectrometry and genomic mapping. Infect. Immun. 73:8109-8118. (Pubitemid 41740298)
56. Macatonia SE, Hsieh CS, Murphy KM, O'Garra A. 1993. Dendritic cells and macrophages are required for Th1 development of CD4 T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent. Int. Immunol. 5:1119-1128. (Pubitemid 23291161)
57. Maira-Litran T, Kropec A, Goldmann DA, Pier GB. 2005. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-β- (1-6)-glucosamine. Infect. Immun. 73:6752-6762. (Pubitemid 41368842)
58. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 10: 173.
59. McGuire TC, Musoke AJ, Kurtti T. 1979. Functional properties of bovine IgG1 and IgG2: interaction with complement, macrophages, neutrophils and skin. Immunology 38:249-256. (Pubitemid 10132459)
60. McKenney D, et al. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:523-1527.
61. Merck. 2011. Update on phase II/III clinical trial of investigational Staphylococcus aureus vaccine, V710. Merck, Whitehouse Station, NJ. http://www.merck.com/newsroom/news-release-archive/research-and-development/ 2011-0411.html.
62. Mills KH, Barnard A, Watkins J, Redhead K. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410. (Pubitemid 23030823)
63. Montgomery CP, et al. 2008. Comparison of virulence in communityassociated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J. Infect. Dis. 198:561-570.
64. Moran GJ, Mount J. 2003. Update on emerging infections: news from the Centers for Disease Control and Prevention. Ann. Emerg. Med. 41:148-151.
65. Morse K, et al. 2012. Association and evidence for linked recognition of type IV secretion system proteins VirB9-1, VirB9-2, and VirB10 in Anaplasma marginale. Infect. Immun. 80:215-227.
66. Nabi Biopharmaceuticals. 2005. Key facts about StaphVAX. Nabi Biopharmaceuticals, Boca Raton, FL. http://www.nabi.com/images/factsheets/ fsStaphVAX.pdf.
67. Nanra JS, et al. 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27:3276-3280.
68. Norimine J, et al. 2003. Stimulation of T-helper cell gamma interferon and immunoglobulin G responses specific for Babesia bovis rhoptryassociated protein 1 (RAP-1) or a RAP-1 protein lacking the carboxyterminal repeat region is insufficient to provide protective immunity against virulent B. bovis challenge. Infect. Immun. 71:5021-5032. (Pubitemid 37070745)
69. Pereira UP, Oliviera DGS, Mesquita LR, Costa GM, Pereira LJ. 2011. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet. Microbiol. 148:117-124.
70. Pie S, Truffa-Bachi P, Pla M, Nauciel C. 1997. Th1 response in Salmonella typhimurium-infected mice with a high or low rate of bacterial clearance. Infect. Immun. 65:4509-4514. (Pubitemid 27463219)
71. Que Q, Helmann JD. 2000. Manganese homeostasis in Bacillus subtilis is regulated by MntR, a bifunctional regulator related to the diphtheria toxin repressor family of proteins. Mol. Microbiol. 35:1454-1468. (Pubitemid 30175521)
72. Rappuoli R. 2000. Reverse vaccinology. Curr. Opin. Microbiol. 3:445-450.
73. Rennermalm A, et al. 2001. Antibodies against a truncated Staphylococcusaureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 19:3376-3383. (Pubitemid 32710286)
74. Schaffer AC, Lee JC. 2008. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents 32:S71-S78.
75. Schaffer AC, et al. 2006. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74:2145-2153.
76. Schroeder JW. 2010. Mastitis control programs: bovine mastitis and milking management. Document AS-1129. North Dakota State University Extension Service, Fargo, ND. http://www.ag.ndsu.edu/pubs/ansci/dairy/as1129.pdf.
77. Sharif S, et al. 1998. Associations of the bovine major histocompatibility complex DRB3 (BoLA-DRB3) alleles with occurrence of disease and milk somatic cell score in Canadian dairy cattle. Anim. Genet. 29:185-193. (Pubitemid 28371571)
78. Shinefield HR. 2006. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 2:65-69.
79. Shinefield H, et al. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491-496. (Pubitemid 34441740)
80. Smith TC, et al. 2009. Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 Is present in midwestern U.S. swine and swine workers. PLoS One 4:e4258.
81. Soavi L, et al. 2010. Methicillin-resistant Staphylococcus aureus ST398, Italy. Emerg. Infect. Dis. 2:346-348.
82. Solis N, Larsen MR, Cordwell SJ. 2010. Improved accuracy of cell surface shaving proteomics in Staphylococcus aureus using a false positive control. Proteomics 10:2037-2049.
83. Stoll H, Dengjel J, Nerz C, Götz F. 2005. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 73:2411-2423. (Pubitemid 40470844)
84. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-16947. (Pubitemid 44737357)
85. Suarez CE, et al. 2000. Characterization of allelic variation in the Babesia bovis merozoite surface antigen 1 (MSA-1) locus and identification of a cross-reactive inhibition-sensitive MSA-1 epitope. Infect. Immun. 68: 6865-6870. (Pubitemid 32463395)
86. Sutten EL, et al. 2010. Anaplasma marginale type IV secretion system proteins VirB2, VirB7, VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine. Infect. Immun. 78:1314-1325.
87. Thomsen I, Dudney H, Creech CB. 2010. Searching for the holy grail of a staphylococcal vaccine. Hum. Vaccin. 6:1068-1070.
88. Thorsby E, Berle E, Nousiainen H. 1982. HLA-D region molecules restrict proliferative T-cell responses to antigen. Immunol. Rev. 66:39-56. (Pubitemid 12001892)
89. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. 2008. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun. 76:5738-5744.
90. van Belkum A, et al. 2009. Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis. 199:1820-1826.
91. van Eijk MJ, Stewart-Haynes JA, Lewin HA. 1992. Extensive polymorphism of the BoLA-DRB3 gene distinguished by PCR-RFLP. Anim. Genet. 23:483-496.
92. Vytvytska O, et al. 2002. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2:580-590. (Pubitemid 34507348)
93. Waters WR, et al. 2011. Tuberculosis immunity: opportunities from studies with cattle. Clin. Dev. Immunol. doi:10.1155/2011/768542.
94. Weichhart T, et al. 2003. Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. Infect. Immun. 71:4633-4641. (Pubitemid 36919930)
95. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. 1996. Roles of IFN-γ and IFN-α in IL-12-induced T helper cell-1 development. J. Immunol. 156:1442-1447.
96. Wertheim HF, et al. 2008. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med. 5:e17.
97. Zhang Y, et al. 2003. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. Vaccine 21:3307-3318. (Pubitemid 36700431)
98. B in growth phase dependent regulation of virulence factors in Staphylococcus aureus. Proteomics 4:3034-3047.